LINC00665 is upregulated in non-small cell lung cancer and can activate the PI3K/AKT pathway by increasing the stability of EZH2, an important component of the initiation complex (PRC2), and mediates the expression of EGFR, thereby counteracting the effect of gefitinib [6]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.